Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aton Pharma has signed a distribution agreement with Meizler Biopharma to commercialize Cuprimine and Syprine in Brazil.
Subscribe to our email newsletter
Cuprimine is currently approved in Brazil, and Meizler is working to obtain regulatory approval of Syprine.
Michael Wells, CEO of Aton Pharma, said: “Cuprimine and Syprine are medically essential products, and Aton is committed to making these products available wherever they are needed. Brazil is the largest country in Latin America, and we are very pleased that we found Meizler to help us address the needs of patients in this country.”